Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07490106
Starting soon Not applicable

Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer

NCT07490106 · tracked via the Priya Life Science France tracker
Sponsor
Centre Oscar Lambret
Phase
Not applicable
Started
2026-10
Last updated
2026-09-17

Condition(s) studied

CancerSarcoma MetastaticGynaecologic CancerDigestive CancersENT CancerMetastatic Cancer or Locally Advanced

Investigational drug(s) / intervention(s)

Early integrated palliative careUsual oncological care

Early integrated palliative care: Patients receive early integrated palliative care at the time of unplanned hospitalization for metastatic or advanced cancer. The intervention includes: * A palliative care consultation * A consultation with the treating oncologist * A multidisciplinary onco-palliative meeting to define a coordinated care plan

Usual oncological care: Patients receive standard oncological care according to institutional practices. Palliative care is provided only when clinically indicated, without systematic early consultation at the time of unplanned hospitalization.

Study summary

This is a multicenter, national, interventional, cluster-randomized study, "stepped wedge" design. This study includes patients with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer, currently undergoing systemic palliative treatment and hospitalized on an unscheduled basis. The study will aim to evaluate the impact of early palliative care implementation for patients with metastatic or advanced cancer identified during an unplanned hospitalization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subjects aged 18 years and older; * Diagnosed with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer; * Currently undergoing systemic palliative treatment (no prospect of cure); * Hospitalized on an unscheduled basis (i.e., unplanned hospitalization for scheduled oncology treatments); * Patient covered by the French social security system; * Informed consent, written and signed. Exclusion Criteria: * PS (WHO) = 4; * Patient receiving end-of-life care; * Patient opposed to the use of medical data for research purposes; * Person deprived of liberty or under guardianship; * Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.

Primary outcome measure(s)

  • Aggressiveness of end-of-life care (composite endpoint) — Assessed during the last 30 days of life and up to 14 days before death
    Treatment will be considered aggressive if at least one of the following criteria is met (composite criterion): * Administration of systemic IV treatment (chemotherapy, targeted therapy, immunotherapy) within 14 days prior to death * At least one visit to the emergency room within 30 days prior to death * At least one admission to intensive care within 30 days prior to death * At least one admission to resuscitation within 30 days prior to death * Death in hospital outside of palliative care

Trial sites (1)

FacilityCityRegionStatus
Centre Oscar Lambret Lille France

More Centre Oscar Lambret trials in France

Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions Recruiting
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer Active, not recruiting
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer Active, not recruiting
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) Recruiting
Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy Active, not recruiting

Other trials for the same condition

Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis Recruiting
Rehabilitation of Taste and Smell Disorders Associated With Chemotherapy Using Aromatherapy Recruiting
Management of Bone Metastases Active, not recruiting
Evaluation of the Therapeutic Approach of Aromatherapy by Olfaction of Essential Oils in Association With Hypnosis in the Management of Patients Followed for Cancer Recruiting
Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07490106 on ClinicalTrials.gov ↗ ← All trials in France